Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | VHL | P40337 | 1/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.30 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
| ▸ | KLK7 | P49862 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6248045 | 0.88 | POLB (0.38) | AAK1KDM4ELMNAHSD17B10PDGFRB | |
| SCHEMBL6494315 | 0.80 | SLC6A2 (0.40) | SLC6A2KDM4ELMNAHSD17B10MEN1 | |
| SCHEMBL6246043 | 0.80 | SLC6A2 (0.40) | SLC6A2AAK1KDM4ELMNAHSD17B10 | |
| SCHEMBL6504655 | 0.80 | SLC6A2 (0.39) | SLC6A2KDM4ELMNAHSD17B10KLK7 | |
| SCHEMBL6244320 | 0.79 | SLC6A2 (0.39) | SLC6A2KDM4ELMNAHSD17B10KLK7 | |
| SCHEMBL6243782 | 0.79 | SLC6A2 (0.39) | SLC6A2KDM4ELMNAHSD17B10KMT2A | |
| SCHEMBL6243560 | 0.79 | AAK1 (0.40) | SLC6A2AAK1KDM4ELMNAHSD17B10 | |
| SCHEMBL6241609 | 0.79 | SLC6A2 (0.39) | SLC6A2AAK1KDM4ELMNAHSD17B10 | |
| SCHEMBL6491765 | 0.78 | SLC6A2 (0.45) | SLC6A2KDM4ELMNAHSD17B10KLK7 | |
| SCHEMBL6247442 | 0.77 | SCN10A (0.41) | SLC6A2KDM4ELMNAHSD17B10KLK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919331-B2 | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-19 | — | — | US | disclosed |
| US-20030207868-A1 | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207868-A1 | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents | MAVS, ZC3HAV1, EIF2AK2 | SLC6A2 4457/4885AAK1 3081/4885KDM4E 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.